Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitor... : Current Opinion in Nephrology
and Hypertension Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors: ready for …

Introduction: In the last decade, concerns have been raised around the use of erythropoiesis-
stimulating agents (ESAs) and intravenous iron in chronic kidney disease (CKD) patients …

Introduction The hypoxia-inducible factor prolyl hydroxylase (HIF-PH) pathway is
responsible for regulating the biosynthesis of erythropoietin (EPO) and maintaining iron …

Hypoxia-inducible factor–prolyl hydroxylase domain inhibitors (HIF-PHIs) are a promising
new class of orally administered drugs currently in late-stage global clinical development for …

With the emergence of hypoxia inducible factor–prolyl hydroxylase inhibitors (HIF-PHIs)
came the hope that using these oral drugs could improve the treatment of the anemia of …

HIF-PHIs have several advantages including oral administration, physiological EPO
secretion, and improved iron utilization. Undoubtedly, HIF-PHIs will pave the new way in the …

Background: Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a new
class of treatment for renal anemia in patients with chronic kidney disease (CKD). This meta …

What is known and objective Previous studies based on small‐sample clinical data proved
that short‐term use of hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHD) inhibitors …

For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …

Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are new
therapeutic agents for anaemia in chronic kidney disease (CKD). We evaluated by meta …